Last reviewed · How we verify
NCT06044324
Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
NA trial testing Repetitive Transcranial Magnetic Stimulation in Treatment Resistant Depression in 42 participants. Enrolling by invitation.
1 December 2025
Quick facts
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 1 November 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Repetitive Transcranial Magnetic Stimulation
Conditions studied
- Treatment Resistant Depression — all drugs for Treatment Resistant Depression →
- Visual Perceptual Weakness — all drugs for Visual Perceptual Weakness →
Sponsor
First Affiliated Hospital of Zhejiang University
Who can join
Adults 18 to 45, any sex, with Treatment Resistant Depression or Visual Perceptual Weakness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Major depressive disorder (MDD) exhibit reduced visual motor perception, which affects prognosis. Metabolic substance changes and abnormal neural activity in the middle temporal visual area (MT) mediate this perceptual dysfunction. The main questions are: •there is no conclusive evidence of impairment of visual motion suppression in treatment-resistant depression (TRD); •it is unknown that functional abnormalities in the MT of TRD patients mediate possible changes in visual perception •lack of treatment for deficit in visual motor perception; •mechanisms behind the intervention process need to be explored. The goal of this clinical trial is to understand the function of visual motor perception in TRD, to validate the effect of the MT on visual motion perception and to explore the effectiveness of the intervention as well as the neurophysiological mechanisms. This study was planned to •explore any differences in visual motor perception and function of MT between TRD and healthy controls; •analyze the influence of neurobiological changes in MT and related brain regions on visual motion perception; •investigate the effects of rTMS intervention in MT for treatment of impaired visual perception function in TRD; •studying potential therapeutic mechanisms by PET/MRI imaging. Participants will divide into TRD group and HC group. Clinical symptoms, scales, visual perception suppression index, PET/MRI, electrophysiology and other clinical data were collected at baseline for both two groups. TRD group received high-frequency rTMS stimulation targeting the MT. Besides, psychological scales, visual suppression index, PET/MRI, electrophysiology and other clinical data were collected during the intervention and after treatment. The researchers will •compare the differences in visual perceptual function and neurobiological characteristics between the TRD group and the HC group in baseline; •analyze the impact of MT and related brain regions in visual motion perception; •compare the suppression index before and after intervention in TRD to discuss the feasibility of rTMS stimulation targeting the MT to improve visual motion perception abnormalities；•utilize the changes in clinical data of PET/MRI and electrophysiology before and after the treatment of TRD group to explore the possible underlying mechanisms during the treatment process.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06044324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Repetitive Transcranial Magnetic Stimulation
Trials testing the same drug.
- NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
- NCT07211490 — rTMS for Cerebellar Ataxia in Children · NA · not yet recruiting
- NCT05139862 — Neurocardiac Predictors of Treatment Response to RTMS in Depression · NA · not yet recruiting
- NCT05883774 — Effects of rTMS on the Anxiety State of Older Patients With GAD · NA · not yet recruiting
- NCT06490965 — Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets · NA · recruiting
Other recruiting trials for Treatment Resistant Depression
Currently open trials in the same condition.
- NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06938841 — Maintenance rTMS for Depression (Maitr-De) · NA · recruiting
- NCT06236711 — Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD) · NA · active not recruiting
- NCT05774665 — Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression · Phase 2 · active not recruiting
- NCT06895863 — COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression · NA · recruiting
Other First Affiliated Hospital of Zhejiang University trials
Trials by the same sponsor.
- NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
- NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
- NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06044324 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06044324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing